Clinical-Pathological Features and Overexpression of Her-2 Receptors in Patients with Prostate Cancer at Bugando Medical Center, Mwanza, Tanzania.
Material type:
TextPublisher number: Wurzburg Road 35, Premises, Post Code: 33102 | P. O. Box 1464 Mwanza, Tanzania | Phone: (255) 28-298-3384 | Fax: (255) 28-298-3386 |Email: vc@bugando.ac.tz | Website: www.bugando.ac.tz Language: English Language: Kiswahili Publication details: Mwanza, Tanzania | Catholic University of Health and Allied Sciences [CUHAS-Bugando] | 2024. Description: 91 Pages; Includes ReferencesSubject(s): Summary:
Abstract:
Background: Overexpression of the human epidermal growth factor receptor 2 (HER-2) has been associated with aggressive progression and high mortality in patients with prostate cancer. HER-2-targeted therapy has been suggested to be of therapeutic importance in prostate cancer patients who do not respond to a commonly used treatment modality. Therefore, this study aims to determine HER-2 overexpression in prostate cancer and its association with clinical-pathological.
Methodology: This was a laboratory-based, cross-sectional study involving 97 patients with prostate adenocarcinoma. Tissue blocks were retrieved for immunohistochemistry (IHC) staining of HER-2 on which tissue microarray was don. Monoclonal antibodies to HER-2(ref no: A0485, lot no: 4140026(DAKO) used. The IHC staining scores of +2 and +3 were considered positive.
Results: A total number of 97 cases were included in this study, the median PSA level was 102ng/ml (range, 60 – 400ng/ml). HER-2 membrane overexpression was observed in 50 of 97 (51.55%) the cases, while 47cases (48.45%) were negative. There was a significant association of HER-2 overexpression with PSA level (P value 0.006) and Gleason grade (P value 0.012).
Conclusion: Prostate cancer in our setting showed a high level of HER-2 overexpression. These findings recommend further studies including clinical trials to be done for all patients with a high Gleason score and elevated PSA for HER-2 overexpression so that they can benefit from targeted therapy (trastuzumab).
| Item type | Current library | Status | Barcode | |
|---|---|---|---|---|
| POSTGRADUATE DISSERTATIONS | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | Not for loan | 20241009130647.0 |
Abstract:
Background: Overexpression of the human epidermal growth factor receptor 2 (HER-2) has been associated with aggressive progression and high mortality in patients with prostate cancer. HER-2-targeted therapy has been suggested to be of therapeutic importance in prostate cancer patients who do not respond to a commonly used treatment modality. Therefore, this study aims to determine HER-2 overexpression in prostate cancer and its association with clinical-pathological.
Methodology: This was a laboratory-based, cross-sectional study involving 97 patients with prostate adenocarcinoma. Tissue blocks were retrieved for immunohistochemistry (IHC) staining of HER-2 on which tissue microarray was don. Monoclonal antibodies to HER-2(ref no: A0485, lot no: 4140026(DAKO) used. The IHC staining scores of +2 and +3 were considered positive.
Results: A total number of 97 cases were included in this study, the median PSA level was 102ng/ml (range, 60 – 400ng/ml). HER-2 membrane overexpression was observed in 50 of 97 (51.55%) the cases, while 47cases (48.45%) were negative. There was a significant association of HER-2 overexpression with PSA level (P value 0.006) and Gleason grade (P value 0.012).
Conclusion: Prostate cancer in our setting showed a high level of HER-2 overexpression. These findings recommend further studies including clinical trials to be done for all patients with a high Gleason score and elevated PSA for HER-2 overexpression so that they can benefit from targeted therapy (trastuzumab).
There are no comments on this title.
Click on an image to view it in the image viewer